PMCQ Logo
English|Carte du Site
Dossiers spéciaux

Demandez au CCPP

Faire une recherche

Afin de soutenir la demande croissante, nous avons modifé la section Demandez au CCPP et l'avons rendu plus facile d'utilisation. Vous pouvez désormais sélectioner la catégorie qui vous interesse dans le menu déroulant et voir les questions qui ont déjà été posées et répondues. Vous pouvez également faire une recherche parmis les questions déjà soumises au CCPP depuis les débuts.

Questions et réponses les plus récentes
468

Hi Patrick, my question is regarding the use of an economic impact study and doing a slide deck around it. Is this not PAAB exempt given that this is not about clinicals but cost savings?

  • Voir réponse [+]
467

To whom it may concern, I am looking for some clarification regarding the definition of a “therapeutic message” per section 6.6 (iv) of the code regarding exemptions: “Use of drug name only in a context not linked to therapeutic or promotional messages, other than those listed in any way.”

Specifically, we would like to send a fax to pharmacists announcing the approval/availability of a new medication along with details required for their ordering systems (i.e. product code, D.I.N., etc.) Can we simply say the name + the type of medication + disease state? For example: Product X, an SSRI for treating depression, is now available in Canada? This doesn’t link to HOW X treats depression or what an SSRI does...

  • Voir réponse [+]
466

What types of claims (if any) are acceptable in email subject lines directed to HCPs?

  • Voir réponse [+]
465

Is it permissible to present efficacy results from real patient cases (provided the cases are anonymous and align with the TMA)?

  • Voir réponse [+]
464

Can unbranded patient materials (covering disease state) have a look & feel/creative that is consistent with a DTC campaign?

  • Voir réponse [+]
463

Is DTC advertising (i.e. patient support website, journal ads, and waiting room brochures) allowed for a schedule D biologic that is not used to treat or cure a schedule A disease?

462

Hi Patrick, We are planning a card that is for patients to carry with them, showing that they have been prescribed product X, which dose, physician contact info, etc (basically a wallet card). We are also preparing a stand for these cards that would sit in the physician's office. Each time they prescribe a patient product X, they grab a card from the stand and fill it out with the patient. The objective of the card is to instruct patients they need to show this card to other HCPs, to ensure these HCPs do not co-administer certain products with product X. Our question: can the card be submitted as patient-directed and the holder as physician-directed, as the holder will never leave the physician's office? The holder really is meant as instruction for the physician. Thank you.

  • Voir réponse [+]
461

Dear PAAB. Can information from Section I and II be used in patient information? Secondly, how does PAAB define something as "promotional" versus factual information for patient information? Thank you.

460

Hi sir. What are the guidelines and regulations for advertising an OTC drug and please can you provide the links?

459

I'm working in a branded patient-information brochure that includes disease information and dosing. All the content is consistent with part III of the TMA. Does this piece require fair balancing copy? If so, what information is required in the fair balance for patient pieces?

Commissaire adjoint  

Patrick Massad
Commissaire adjoint

Pour visionner le
Code d’agrément de la publicité du CCPP
cliquez ici
Le Conseil Consultatif de
Publicité Pharmaceutique
Conférences à venir

27 février 2018

Perspective sur les changements du CEPMB; Impact sur notre industrie – Ce que vous devez savoir

Accueil et déjeuner : 7 h 0
Conférence : 7 h 30 pile - 9 h 00

Cliquez ici pour vous inscrire